Jim Simons Aligos Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 808,260 shares of ALGS stock, worth $557,699. This represents 0.0% of its overall portfolio holdings.

Number of Shares

808,260

Previous 489,960 64.96%

Holding current value

$557,699

Previous $325,000 143.69%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.64 - $1.13 $203,712 - $359,678	318,300 Added 64.96%	808,260 $792,000
Q4 2023 Feb 13, 2024	BUY	$0.56 - $0.8 $94,416 - $134,880	168,600 Added 52.46%	489,960 $325,000
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.06 $77,528 - $115,746	-109,195 Reduced 25.36%	321,360 $240,000
Q2 2023 Aug 11, 2023	SELL	$0.89 - $1.36 $19,851 - $30,334	-22,305 Reduced 4.93%	430,555 $418,000
Q1 2023 May 12, 2023	SELL	$0.87 - $2.11 $69,078 - $167,534	-79,400 Reduced 14.92%	452,860 $396,000

Q4 2022 Feb 13, 2023	SELL	$0.89 - $1.08 $176,520 - $214,205	-198,338 Reduced 27.15%	532,260 $507,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $1.6 $182,852 - $276,003	-172,502 Reduced 19.1%	730,598 $804,000
Q2 2022 Aug 12, 2022	BUY	$1.04 - $2.14 $562,417 - $1.16 Million	540,786 Added 149.26%	903,100 $1.09 Million
Q1 2022 May 13, 2022	BUY	$2.08 - $12.2 $640,253 - $3.76 Million	307,814 Added 564.8%	362,314 $779,000
Q4 2021 Feb 11, 2022	BUY	$11.48 - $17.69 $14,924 - $22,997	1,300 Added 2.44%	54,500 $647,000
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $775,124 - $942,703	53,200 New	53,200 $825,000

Others Institutions Holding ALGS

# of Institutions

Shares Held

46.2M

Call Options Held

6.11M

Put Options Held

200

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $27.4M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account